IL6 and COVID-19: The benefits of IL-6 inhibition in COVID-19 are not seen in some trials (54), but the REMAP-CAP study of critically ill patients with COVID-19 suggests IL-6 receptor inhibition has a place in those with the most severe forms of COVID-19 (8).